top of page

I3LUNG
INTEGRATIVE SCIENCE, INTELLIGENT DATA PLATFORM FOR INDIVIDUALIZED LUNG CANCER CARE WITH IMMUNOTHERAPY

CLINICAL TRIAL DETAILS
I3LUNG IS A EUROPEAN PROJECT FUNDED UNDER THE FRAMEWORK OF THE H2020 CALL "ENSURING ACCESS TO INNOVATIVE, SUSTAINABLE AND HIGH-QUALITY HEALTH CARE". THE PROJECT AIMS TO DEVELOP A MEDICAL DEVICE TO PREDICT IMMUNOTHERAPY EFFICACY FOR NSCLC PATIENTS THROUGH THE INTEGRATION OF MULTISOURCE DATA (REAL WORLD AND MULTI-OMICS DATA) FROM A RETROSPECTIVE AND A PROSPECTIVE PHASE. THE FINAL OBJECTIVE IS THE ESTABLISHMENT OF A WORLDWIDE DATA SHARING AND ELABORATION PLATFORM (DSEP) AND AN INDIVIDUALIZED PATIENT DECISION AID SYSTEM (iPDAS) TO SUPPORT CLINICIANS IN TREATMENT SELECTION.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
LUNG
6
2200
N/A
Spain, Greece, Italy, Israel, USA, Germany
Recruitment
TRIAL OVERVIEW
PRESS RELEASE
-
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
-
Dr. Sofia Braga
Dr. Silvi AntolÃn
Dr. Escrivá de RomanÃ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page
